Home/Pipeline/ES135

ES135

Acute Spinal Cord Injury

Phase 3Active

Key Facts

Indication

Acute Spinal Cord Injury

Phase

Phase 3

Status

Active

Company

Eusol Biotech, Eusol Biotech

About Eusol Biotech

Taiwanese biotech advancing rhFGF1‑based therapies for nerve regeneration and niche generics.

View full company profile

About Eusol Biotech

Taiwanese biotech advancing rhFGF1‑based therapies for nerve regeneration and niche generics.

View full company profile

Therapeutic Areas

Neurology Pain Cardiovascular Psychiatry

Other Acute Spinal Cord Injury Drugs

Drug	Company	Phase	Status
AMFX-200S	Amphix Bio	Preclinical	Active
KP-100IT (HGF protein)	Kringle Pharma	Phase 3	Completed Phase III single-arm study; additional study plan in progress
ExoPTEN	NurExone Biologic	Preclinical	Active
OPC1	Lineage Cell Therapeutics	Phase 1/2a	Active